Anastrozol vs Letrozol vs Exemestane
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Anastrozole (Arimidex) | Letrozole (Femara) | Exemestane (Aromasin) | |
|---|---|---|---|
| What it is | Prescription aromatase inhibitor for breast cancer that bodybuilders also use to lower estrogen; banned on the doping list. | Prescription aromatase inhibitor for breast cancer that lowers estrogen; bodybuilders also use it, and it is banned in competitive sport. | Prescription aromatase inhibitor for breast cancer that bodybuilders use to keep estrogen low; banned on the anti-doping list. |
| MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | Reversible aromatase inhibitor; lowers estrogen levels by over 90% | Non-steroidal aromatase inhibitor; estrogen can fall by up to about 99% | Steroidal "suicide" (irreversible covalent) CYP19 aromatase inhibitor – a single dose permanently inactivates a portion of the pool |
| Dosing (AAS) | 0.25-1 mg EOD-2x/week titrated by bloodwork (E2 trough 20-30 pg/mL LC-MS/MS) | 0.25-1.25 mg EOD bloodwork-titrated; gyno reversal 2.5 mg/day × 14-21 days | 12.5-25 mg EOD or 25 mg/day |
| Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed. | ~50 hours (single daily dose, steady-state day 7) | ~42 hours | ~27 h (parent), ~24-48 h active metabolite; pharmacodynamic effect 5-7 days |
| OnsetOnsetThe time from dosing until a measurable effect appears. | E2 reduction measurable 24-48 h, full effect 5-7 days | E2 reduction measurable 24-48 h, plateau 4-6 days | E2 reduction measurable 12-24 h, full effect 3-5 days |
| Legal statusLegal / WADA statusThe compound’s regulatory status (e.g. prescription) and its place on the WADA prohibited-in-sport list. | FDA + EMA Rx, HU + PL approved, WADA S4.1 banned | FDA + EMA Rx, HU + PL approved, WADA S4.1 banned | FDA + EMA Rx, HU + PL approved, WADA S4.1 banned |
| Full entry | Open → | Open → | Open → |
Anastrozole, letrozole or exemestane: how do they differ?
All three block the same enzyme, the one that turns androgens into oestrogen, but not in the same way. Anastrozole and letrozole are non-steroidal and bind the enzyme reversibly; of the two, letrozole is described as the stronger blocker. Exemestane is steroidal and permanently switches off the enzyme molecules it attaches to: activity returns only as the body builds new enzyme. It is also the only one of the three whose entry notes a mildly androgenic breakdown product that lowers SHBG, so free testosterone rises measurably.
